Published in Expert Rev Neurother on November 01, 2011
Behavioral and psychological symptoms in Alzheimer's disease. Biomed Res Int (2014) 0.79
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med (2012) 4.22
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res (2008) 1.84
Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry (2003) 1.40
Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement (2008) 1.39
Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry (2005) 1.27
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry (2007) 1.24
Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet (2014) 1.19
Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55-75 years of age: a pilot study. Depress Anxiety (2004) 1.03
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A (2012) 0.95
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Am J Alzheimers Dis Other Demen (2012) 0.89
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig (2008) 0.85
Preliminary examination of progression of Alzheimer's disease in a rural Southern African American cohort. Arch Clin Neuropsychol (2007) 0.84
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry (2012) 0.84
Spinal cord injury: how can we improve the classification and quantification of its severity and prognosis? J Neurotrauma (2014) 0.81
The many faces of psychosis in the elderly. Curr Opin Psychiatry (2007) 0.79
Sertraline for the treatment of depression in Alzheimer disease: genetic influences. J Geriatr Psychiatry Neurol (2011) 0.78
Elderly veterans with combat-related posttraumatic stress disorder in specialty care. J Nerv Ment Dis (2004) 0.77
Commentary: "Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?" by Claudio Costantini, Rekha M.K. Kolasani, Luigi Puglielli. Alzheimers Dement (2005) 0.75